research Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata
1% anthralin ointment is effective and safe for treating severe alopecia areata in children.
Search
for
Sort by
Research
210-240 / 1000+ results research 0350 Impact of switching janus kinase inhibitors in the treatment of severe alopecia areata
Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.
research Serenoa repens: Does it have any role in the management of androgenetic alopecia?
Serenoa repens is not proven effective for hair loss and may delay prostate cancer detection.
research Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
research Predominance of CD27-PD-1- Effector Memory T Cells Re-Expressing CD45RA Characterizes Treatment-Resistant Severe Alopecia Areata
CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.
research 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
IL-15 helps maintain hair growth and protects the immune status of hair follicles.
research Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
research Emerging Unconventional Therapies for Alopecia Areata
New therapies for alopecia areata show potential but need more research.
research Emerging drugs for the treatment of alopecia areata
New drugs for alopecia areata show promise but aren't universally effective, and hair loss often returns after stopping treatment.
research Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study
Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
research Serenoa repens: Does it have any role in the management of androgenetic alopecia?
Serenoa repens is not proven effective for hair loss and may delay prostate cancer detection.
research Successful hair regrowth in an acute diffuse form of alopecia areata during oral tacrolimus treatment in a patient with rheumatoid arthritis
Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
research Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
Dupilumab helps children with alopecia areata regrow hair safely.
research Effect of Fexofenadine as an Adjunct to DPCP in Non-Atopic Patients with Alopecia Areata: A Randomized Clinical Trial
Fexofenadine reduces discomfort but doesn't significantly improve hair regrowth in Alopecia Areata treatment.
research Hair Regrowth in a Child with Seasonal Alopecia Areata While Receiving Subcutaneous Aeroallergen Immunotherapy: A Case Report
Immunotherapy helped a 5-year-old boy regrow hair and prevent seasonal alopecia areata.
research 5‐alpha‐reductase inhibitor treatment for frontal fibrosing alopecia: an evidence‐based treatment update
5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.
research Comparing the burden of illness in patients with alopecia areata vs atopic dermatitis in the US population from a payer perspective
Alopecia areata and atopic dermatitis have similar healthcare costs, but alopecia areata leads to more outpatient and long-term disability expenses.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Baricitinib for alopecia areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research 706 Predictive modeling of patient response to JAK/STAT inhibitors and dynamic patient-matching
Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
research Antianaphylactic activity of alcoholic extract ofEclipta alba
Alcoholic extract of Eclipta alba may help treat allergies and is safe at high doses.
research Candida antigen immunotherapy versus steroid in the treatment of alopecia areata
Candida antigen is an effective and promising treatment for alopecia areata.
research Alopecia Areata - Current and Emerging Therapies
New treatments like JAK inhibitors offer hope for hair regrowth in severe alopecia areata.
research Microneedling with Triamcinolone acetonide versus Intralesional Triamcinolone acetonide in treatment of Alopecia Areata
Microneedling with triamcinolone is a safe, effective, and less painful treatment for alopecia areata.
research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.